SERUM OSTEOPONTIN LEVEL IS ASSOCIATED WITH PRESENCE OF ATRIAL FIBRILLATION IN CALCIFIC AORTIC VALVE STENOSIS

Cover Page

Cite item

Full Text

Abstract

Identification of risk factors associated with presence of atrial fibrillation (AF) in patients with aortic valve stenosis (AS) remains to be unraveled.The aim of the study was to investigate relationship between profibrotic biomarkers and presence of AF in AS patientsMethods. 191 patients (29,8% male, 77,7±0,59 years) with AS (defined as aortic valve area (AVA) ≤ 2,0 sm2) were enrolled in the study. Clinical, echocardiographic and biochemical variables, including serum TGFβ1 and osteopontin levels were compared between 2 groups of patients: with and without AF. Results. 83(36,5%) of AS patients had AF. In logistic regression models independent associations between AVA index (p=0,040), left atrial volume (p=0,021), OPN (р=0,009) and presence of AF were found. Patients with serum OPN level > 10,05 ng/ml had twice more higher AF incidence comparedto patients with serum OPN level ≤ 10,05 ng/ml (53,8% and 29,2%, respectively, p=0,020).Conclusion. Serum OPN level was independently associated with presence of AF in AS patients, thus we speculate on it’s predominant profibrotic role in the left atrium.

About the authors

T A Tipteva

ФГБУ ДПО «ЦГМА» УДП РФ

Email: ttipteva@yandex.ru
аспирант кафедры терапии, кардиологии и функциональной диагностики с курсом нефрологии ФГБУ ДПО «ЦГМА» УДП РФ

O S Chumakova

ГБУЗ ГКБ №17 ДЗМ

Email: chumakovaolga@bk.ru
к.м.н., доцент кафедры терапии, кардиологии и функциональной диагностики с курсом нефрологии ФГБУ ДПО «ЦГМА» УДП РФ; врач-кардиолог ФГБУ ГКБ №17 ДЗМ

N E Reznichenko

ГБУЗ ГКБ №17 ДЗМ

Email: phe777@mail.ru
к.м.н., заведующая лабораторией ФГБУ ГКБ №17 ДЗМ

V I Safaryan

ГБУЗ ГКБ №51 ДЗМ

Email: vahtang1985@yandex.ru
врач-терапевт ГБУЗ ГКБ №51 ДЗМ, врач-функциональной диагностики ГБУЗ ГКБ №51 ДЗМ

T N Baklanova

ГБУЗ ГКБ №17 ДЗМ

Email: tnbaklanova@yandex.ru
зам. главного врача по медицинской части ФГБУ ГКБ №17 ДЗМ, врач-кардиолог ФГБУ ГКБ №17 ДЗМ

N M Voloshina

ГБУЗ ГКБ №17 ДЗМ

Email: natalia.voloshina@bk.ru
заведующая кардиологическим отделением ФГБУ ГКБ №17 ДЗМ

D A Zateyshchikov

ФГБУ ФНКЦ ФМБА России

Email: dz@bk.ru
д.м.н., профессор, руководитель первичного сосудистого отделения ГБУЗ ГКБ №51 ДЗМ; заведующий кафедрой терапии, кардиологии и функциональной диагностики с курсом нефрологии ФГБУ ДПО «ЦГМА» УДП РФ; ведущий научный сотрудник лаборатории генетики ФГБУ ФНКЦ ФМБА России

References

  1. Greve AM, Gerdts E, Boman K, Gohlke-Baerwolf C, et al. Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. International journal of cardiology 2013; 166(1):72-76.
  2. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012; 14(1):8-27.
  3. Santos IJ, Rodes-Cabau J, Urena M, et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. Journal of the American College of Cardiology 2012; 59(2):178-188.
  4. Драпкина ОМ, Емельянов АВ. Предсердный фиброз морфологическая основа фибрилляции предсердий. Рациональная фармакотерапия в кардиологии 2013; 9(4): 417-419.
  5. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. Journal of the American College of Cardiology 2012; 60(19):1854-1863.
  6. Chotchaeva Z, Shcheglova EV, Boeva OI, Hait GY, et al. Matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinases type 1 serum concentrations and genetic polymorphism in senile aortic stenosis. Advances in gerontology 2015; 28(2):222-227.
  7. Бабанин В.С., Докина Е.Д., Берестовая Н.А., Алексеева Л.А.: Распространенность кальцификации клапанных структур сердца у женщин с первичным остеопорозом. Кремлевская медицина Клинический вестник 2010;(3):32-34).
  8. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-β1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118(1):10-24.
  9. Lorenzen JM, Schauerte C, Hübner A, Kölling M, et al. Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. European heart journal 2015; 36 (32): 2184-2196.
  10. Lang RM, Badano LP, Mor-Avi V, Afilalo J, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography 2015; 28(1):1-39. e14.
  11. Tarantini G, Mojoli M, Windecker S, et al. Prevalence and Impact of Atrial Fibrillation in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. An Analysis From the SOURCE XT Prospective Multicenter Registry 2016; 9(9):937-946.
  12. Bollmann A, Husser D, Steinert R, Stridh M, et al. Echocardiographic and electrocardiographic predictors for atrial fibrillation recurrence following cardioversion. Journal of cardiovascular electrophysiology 2003; 14(s10):S162-S165.
  13. Jian B, Narula N, Li Q-y, Mohler ER, III, Levy RJ. Progression of aortic valve stenosis: TGF-{beta}1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 2003; 75(2):457-465.
  14. Verheule S, Sato T, Everett T, Engle SK, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1. Circulation research 2004; 94(11):1458-1465.
  15. Attaran S, Sherwood R, Dastidar MG, El-Gamel A. Identification of low circulatory transforming growth factor β-1 in patients with degenerative heart valve disease. Interactive cardiovascular and thoracic surgery 2010; 11(6):791-793.
  16. Li J, Yang Y, Ng CY, Zhang Z, Liu T, Li G. Association of plasma transforming growth factor-β1 levels and the risk of atrial fibrillation: a meta-analysis. PloS one 2016; 11(5):e0155275.
  17. O’Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin Is Expressed in Human Aortic Valvular Lesions. Circulation 1995; 92(8):2163-2168.
  18. Passmore M, Nataatmadja M, Fung YL, Pearse B, Gabriel S, Tesar P, Fraser JF. Osteopontin alters endothelial and valvular interstitial cell behaviour in calcific aortic valve stenosis through HMGB1 regulation. European Journal of Cardio-Thoracic Surgery 2015; 48(3):e20-e29.
  19. Brown LF, Berse B, Van De Water L, Papadopoulos-Sergiou A, et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Molecular biology of the cell 1992; 3(10):1169-1180.
  20. Yu P-J, Skolnick A, Ferrari G, Heretis K, et al. Correlation between plasma osteopontin levels and aortic valve calcification: potential insights into the pathogenesis of aortic valve calcification and stenosis. The Journal of thoracic and cardiovascular surgery 2009; 138(1):196-199.
  21. Sponder M, Fritzer-Szekeres M, Litschauer B, Binder T, Strametz-Juranek J. Endostatin and osteopontin are elevated in patients with both coronary artery disease and aortic valve calcification. IJC Metabolic & Endocrine 2015; 9:5-9.
  22. Thum T, Lorenzen JM. Cardiac fibrosis revisited by microRNA therapeutics. Circulation. 2012;126:800-802
  23. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends in cell biology 2006; 16(2):79-87.
  24. Grammer JB, Böhm J, Dufour A, Benz M, Lange R, Bauernschmitt R. Atrial fibrosis in heart surgery patients. Basic research in cardiology 2005; 100(3):288-294.
  25. Güneş HM, Babur Güler G, Güler E, et al. Relationship between serum osteopontin level and atrial fibrillation recurrence in patients undergoing cryoballoon catheter ablation. Turk Kardiyol Dern Ars 2017; 45(1):26-32.
  26. Rosenberg M, Zugck C, Nelles M, et al. Osteopontin, a New Prognostic Biomarker in Patients With Chronic Heart Failure CLINICAL PERSPECTIVE. Circulation: Heart Failure 2008; 1(1):43-49.
  27. Lopez FL, Agarwal SK, MacLehose RF, Soliman EZ, et al. Blood Lipid Levels, Lipid-Lowering Medications, and the Incidence of Atrial Fibrillation Clinical Perspective. Circulation: Arrhythmia and Electrophysiology 2012; 5(1):155-162.

Copyright (c) 2017 Tipteva T.A., Chumakova O.S., Reznichenko N.E., Safaryan V.I., Baklanova T.N., Voloshina N.M., Zateyshchikov D.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies